Health News SKY-HERO and AARDVARK Tactical Announce World’s First NDAA-Compliant Interior sUAS Platform admin, October 27, 2022 LOKI Mk2 LA VERNE, Calif. – October 27, 2022 – (Newswire.com) AARDVARK Tactical and Sky-Hero are pleased to announce the release of the world’s first National Defense Authorization Act (NDAA)-compliant interior use tactical sUAS, LOKI Mk2US. The Mk2US is built to comply with the rigorous standards set forth in the NDAA and the recent Department of Defense black-listing of certain Chinese-made drone parts and technologies. In response, Sky-Hero, the world’s leading manufacturer of interior tactical robotics, redesigned and resourced the LOKI Mk2 to eliminate all of the covered Chinese components and replace them with European or American items. Speaking about this new drone, Yves Coppye, CEO of Sky-Hero, stated: “We have been asked by many of our top users around the world to ensure that all major components are built by NATO countries. After two years of work, we are pleased to announce that we have reengineered and redesigned these components and located American or European sources for them.” Jon Becker, AARDVARK’s CEO, echoed this by stating: “We are extremely excited to see Sky-Hero release an NDAA-compliant version of LOKI. While there are a number of products on the market that claim to be American, in reality, the large majority of drones are simply built with Chinese-made parts and at best assembled in the U.S. LOKI Mk2US has always been made by NATO allies and now every NDAA-covered component will be too.” The LOKI Mk2US will begin shipping in Q1 of 2023. LOKI Mk2 is sold exclusively in North America by AARDVARK. Visit LOKI.AARDVARKTactical.com to learn more. About AARDVARK: Founded in 1987, AARDVARK is a leading manufacturer, distributor, and system integrator of products to protect tactical operators from Local, State, Federal, and Military Units. AARDVARK is headquartered in La Verne, CA. About SKY-HERO: Founded in 2013, Sky-Hero is a dynamic, flexible, fast-growing company specializing in drones and robotics and located in Brussels. With a target market in civil security, their clients range from Police Special Forces to International Security companies, mountain rescue teams, and firefighters. About LOKI-Mk2 – LOKI Mk2 is a rugged, purpose-built sUAS intended to act as a scout for close-quarter, confined space, and indoor missions. LOKI Mk2 requires no internet service, no GPS, no phone or tablet connection, and has no forced software updates, making it mission capable in seconds from virtually anywhere. LOKI Mk2 performs in almost any lighting condition, seamlessly transitioning from sunlight to complete darkness. Contact Information: Brent Doan Director of Sales bdoan@aardvarktactical.com 909-451-6105 Related Files _F8A2177.jpg loki2_3qtr_top.sitting.rf_img_1235.jpg Press Release Service by Newswire.com Original Source: SKY-HERO and AARDVARK Tactical Announce World’s First NDAA-Compliant Interior sUAS Platform The post SKY-HERO and AARDVARK Tactical Announce World’s First NDAA-Compliant Interior sUAS Platform first appeared on Enrose Magazine. Continue Reading
Health News AQuity Earns Ninth Consecutive #1 Ranking in 2022 Black Book™ Research Survey for Virtual Scribes, Transcription, and Clinical Document Capture admin, October 27, 2022 Black Book™ Research recognizes AQuity Solutions as the best overall outsourced document capture solutions provider for their virtual scribe and medical transcription solutions, reducing documentation time and alleviat… The post AQuity Earns Ninth Consecutive #1 Ranking in 2022 Black Book™ Research Survey for Virtual Scribes, Transcription, and Clinical Document Capture first appeared on Enrose Magazine. Continue Reading
Health News TOOTRiS Provides Free Child Care Access to First Responders Nationwide admin, October 27, 2022 In Honor of National First Responders Day, TOOTRiS Child Care On-Demand Offers Free, Year-Long Access TOOTRiS Child Care On-Demand … The post TOOTRiS Provides Free Child Care Access to First Responders Nationwide first appeared on Enrose Magazine. Continue Reading
Health News SQAIRZ Launches GFP Baseball Shoe and Partners With Louisville Slugger Hitting Science Center admin, October 27, 2022 As part of its commitment to performance-driven innovation in athletic footwear, SQAIRZ has made its first expansion to a sport other than golf. After a year of testing in partnership with Louisville Slugger Hitting Science Center, the custom-designed, performance-focused SQAIRZ GFP baseball turf shoe has already shown the ability to create marked change in a baseball player’s game. WINDHAM, N.H. – October 27, 2022 – (Newswire.com) SQAIRZ, the footwear company seeing incredible growth in golf shoes through its focus on performance and comfort, announced today the launch of the new SQAIRZ GFP baseball turf shoes and a partnership with Louisville Slugger Hitting Science Center. SQAIRZ has been making waves in golf with its patented square-toe design, which has been proven to increase balance, consistency, swing speed and distance. In less than three years, SQAIRZ has won on both the PGA Tour and PGA Champions Tour and has been named among the Best Golf Shoes by Golf Digest. As part of its commitment to performance-driven innovation, SQAIRZ has made its first expansion to a sport other than golf. After a year of testing in partnership with Louisville Slugger Hitting Science Center, the custom-designed, performance-focused SQAIRZ GFP baseball turf shoe has already shown the ability to create marked change in a player’s game, impacting running, pitching, fielding, and hitting. Players wearing SQAIRZ at all levels—Major League, Minor League, and high school—showed elevated performance in all areas of the game. On the heels of these incredible results, SQAIRZ has entered into a partnership with Louisville Slugger Hitting Science Center to market a SQAIRZ performance shoe honed specifically for baseball. “Balance, stability, and ground force production have not been given the attention they deserve in sports,” said Robert Winskowicz, founder of SQAIRZ. “Controlling these three performance elements through the right shoe is critical to consistently maximizing your performance in most sports. I am very proud to partner with Louisville Slugger Hitting Science Center. Their team of experienced baseball players and coaches have put SQAIRZ through their paces, analyzing their performance in all aspects of the game, whether base running, fielding, pitching, or batting, and we are thrilled with the impressive results.” “I look at swings at every level of the game, from 10U Travel Ball Players to Major League Baseball All Stars,” said Chad Miller, founder of Louisville Slugger Hitting Science Center. “I have never seen a product that has such an amazing impact on a player like the SQAIRZ GFP. With our advanced-level amateur players, we have recorded an average increase of 2.6 mph of exit velocity (approximately 26 feet of distance) when using the SQAIRZ turf shoe versus traditional turf shoes. That is the difference between making a varsity team, getting a college scholarship, or being drafted.” “As a current Major League Baseball Hitting Coordinator I constantly work with hitters and teach them how to use the ground to generate more power and balance through surface area contact,” said Dave Hansen, Cincinnati Reds Hitting Coordinator and former MLB slugger. “The SQAIRZ GFP shoe is the most revolutionary and game-changing technology that I have seen in my 31 years of professional baseball playing and coaching career. I have been using the SQAIRZ Turf Shoes in our training sessions with the players in our organization. The instant feedback and results that the SQAIRZ shoes produce are something that I have never seen in baseball.” “Over the past 25 years, I have studied the effects of physical function and footwork and how these two aspects relate to ground reaction forces,” said Philip Stotter, MS, CEP, Sports Biomechanist, and MLB Sports Science Consultant. “A poor relationship at the foot level will cause the energy that is used for a movement like a swing or a pitch to leak into compensatory movements and cause an athlete to lose their balance and connection with the ground. Because footwear is the only piece of equipment that stands between a person and the ground, finding the right footwear can be game-changing. Ground reaction in sports is something I test on a daily basis, and what we are finding with SQAIRZ is game-changing.” The new SQAIRZ GFP is available for presale at www.sluggerscience.com, with plans to begin shipping by early 2023. About SQAIRZ Athletic shoes should be more than mere accessories, they are the foundation of every movement and should be drivers of true performance. The vision for SQAIRZ started on a New England driving range, where a pair of square-toed dress shoes spurred a visual realization. It continued through years of research into ground force reaction, biomechanics, and foot movement. It has culminated in award-winning shoes, now played on Tour, that will help every golfer hit more accurate and powerful shots, and soon to be accelerating performance on baseball diamonds across the country. SQAIRZ is inspired by developing performance-enhancing shoes that will change the shape of your game. Contact Information: Chad Miller Founder, Louisville Slugger Hitting Science Center sqairz@sluggerscience.com 1-502-445-3232 Savannah Smith Marketing Director, SQAIRZ LLC savannah@sqairzgolf.com 1-888-793-7779 Related Images Press Release Service by Newswire.com Original Source: SQAIRZ Launches GFP Baseball Shoe and Partners With Louisville Slugger Hitting Science Center Continue Reading
Health News HealthJoy Raises $60M Series D to Power HR Leaders Through a New Era of Workplace and Healthcare Benefits admin, October 27, 2022 Funding round led by Valspring Capital, a new growth equity fund founded by the former Bain Capital Ventures healthcare investment team; brings total funding raised to date to more than $108M. … The post HealthJoy Raises $60M Series D to Power HR Leaders Through a New Era of Workplace and Healthcare Benefits first appeared on Enrose Magazine. Continue Reading
Health News Immuware Launching New Referral Program Where Organizations Can Earn Credit admin, October 27, 2022 The referral program is the latest in the software company’s push to improve immunization and illness tracking in hospitals, educational institutions, and other organizations Immuware Immuware CHICAGO – October 27, 2022 – (Newswire.com) Immuware, a Chicago-based software company that provides innovative immunization and illness tracking systems, is excited to announce the launch of a new referral program for clients. The recently developed program will reward clients for referrals by providing referring organizations with a credit of $2,500 toward their next invoice for any referrals that sign a contract of three years or more. The new referral program is intended to thank Immuware’s existing clients for recommending the company’s software products to other users. And because the program is ongoing, organizations can continue to refer Immuware as many times as they’d like, receiving a $2,500 credit each time a client signs on for a three-plus-year contract term. Immuware’s quick-to-deploy software solutions are essential for organizations that require tracking illness and injuries among employees. Through key system features like real-time dashboards, automated end-to-end compliance workflows, HIPAA-secure cloud hosting, and a permission-based online employee portal, Immuware makes it easy to maintain accurate data on employee immunization, illness, and injury status, regardless of the size or scope of a workforce. Clients enjoy flexible and scalable features for employee and occupational health monitoring, with comprehensive solutions that raise the bar for what organizations can expect out of their health tracking software. And through the referral program, Immuware hopes to help even more clients save time and money and reduce the errors that can come with manual reporting. Immuware clients have been shown to reach compliance at least 40% faster than non-users, and have a dedicated partner in tracking all of the data that matters to the health of their workforce and facilities. This means that not only are organizations able to easily meet mandatory regulatory requirements, but they are also able to better protect the employees who are crucial to their day to day operations. Current Immuware clients are encouraged to participate in the new referral program and take advantage of big savings on one or more future invoices. As previously mentioned, clients will be credited $2,500 for every organization they refer that signs on for a three or more year contract with Immuware, and can gain this credit every time they make an eligible referral. To learn more, please visit the Immuware homepage for additional information on Immuware software features and benefits, or contact Immuware directly today. About Immuware Immuware is a software company and consulting firm that provides businesses in the healthcare, energy, education, and government sectors with secure and easy-to-use health tracking solutions. Immuware applications include innovative vaccination management and illness tracking software, plus streamlined compliance status dashboards that increase accountability and take the guesswork out of identifying compliance gaps. Visit www.immuware.com for more information. Contact:Immuware(312) 505-1443info@immuware.com Contact Information: Alexandria Onwuteaka Marketing & Sales Coordinator info@immuware.com 3125051443 Press Release Service by Newswire.com Original Source: Immuware Launching New Referral Program Where Organizations Can Earn Credit The post Immuware Launching New Referral Program Where Organizations Can Earn Credit first appeared on Enrose Magazine. Continue Reading
Health News TODAY: Gb Sciences’ President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit admin, October 27, 2022 At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences’ proprietary PhAROS drug discovery platform. Gb Sciences LAS VEGAS – October 27, 2022 – (Newswire.com) Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (GBLX-OTC), a leading plant-inspired, biopharmaceutical research and drug development company, is demonstrating their AI-enabled drug discovery engines’ ability to identify novel plant-inspired pharmaceuticals today at the 10th Annual Drug Discovery Strategic Summit in San Francisco, California. In her session entitled “The Use of an AI-enabled Drug Discovery Engine to Identify Plant-Inspired Pharmaceuticals,” Dr. Small-Howard will introduce PhAROS™, Gb Sciences’ proprietary AI-enabled drug discovery platform. Dr. Small-Howard will also present case studies establishing how the company has utilized PhAROS™ to combine information from plant-based medical systems with modern in silico drug discovery tools that identify novel plant-inspired therapies for treating critical medical needs. “Gb Sciences is combining knowledge from plant-based traditional medical systems with modern in silico drug discovery tools. We are leveraging our AI-enabled platform with its unique database of known traditional medical plant species to uncover novel minimum essential mixtures of ingredients with therapeutic benefits and reduced side effect profiles. Our AI-enabled drug discovery platform also reduces the time and money needed to get results,” said Dr. Andrea Small-Howard. “With current drug discovery efforts failing to deliver on some critical medical needs, such as non-opioid treatments for chronic pain or novel options for patients suffering with anxiety and depression, we are establishing the value in exploring plants associated with traditional medicines to discover new drug molecules and simplified mixtures.” Dr. Andrea Small-Howard of Gb Sciences was recently featured on MarketScale’s “IDC with Kevin Stevenson” podcast in an episode entitled “Bringing Medicines to Market Faster Through Analytics and Machine Learning” where she discussed the need for digital transformation in the biopharma industry and the fact that Gb Sciences is ahead of the majority of the industry through the development and use of their PhAROS™ platform for drug discovery. To learn more about Gb Sciences, visit www.gbsciences.com. About Gb Sciences and GbS Global Biopharma Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com. Contact Information: Madeleine Moench madeleine@newswire.com Press Release Service by Newswire.com Original Source: TODAY: Gb Sciences’ President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit The post TODAY: Gb Sciences’ President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit first appeared on Enrose Magazine. Continue Reading
Health News Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test admin, October 27, 2022 Senzo, a global life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, today announced a partnership with BARDA, part of the Administration for Strategic Preparedness and Response (ASPR), in the US Department of Health and Human Services (HHS) to assist in bringing Senzo’s Amplified Lateral Flow (ALF) COVID-19 test in achieving U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) to market. PHILADELPHIA – October 27, 2022 – (Newswire.com) This contract follows Senzo’s recent announcements about the receipt of ISO 13485:2016 certification, and completing a $2 million Pre-Series A financing led by BioAdvance, to apply the ALF technology to other targets such as Flu A/B, Tuberculosis, HIV, C. diff, Sexual Health, and Hepatitis C. Senzo’s core innovation is its Amplified Lateral Flow (ALF) technology which significantly increases the sensitivity of traditional-format lateral flow tests while maintaining specificity. The end result is a fast, low-cost, easy-to-use lateral flow test with the same accuracy as a PCR test, the industry’s gold standard test. The ability to incorporate amplification into a lateral flow test has long been a goal for diagnostics test makers but one which has proven difficult to achieve due to the tendency for amplified tests to return false positives. Senzo recently announced results from a blinded, third-party R&D study demonstrating that its Amplified Lateral Flow (ALF) COVID-19 antigen test was 100% accurate in concordance with PCR testing, even in cases with very low viral levels, which could allow for substantially better and earlier detection of virus compared to current lateral flow tests. “The faster we can accurately diagnose, the sooner we can take action, begin treatment, and the better the patient outcome. Creating a low-cost, user-friendly diagnostic test which delivers PCR accuracy at the point of care, without the need to send a sample to a laboratory, will improve healthcare— it’s that simple. BARDA’s support of our ALF technology will be instrumental in helping us advance our ultimate goal of bringing ALF tests to market,” said Jeremy Stackawitz, CEO of Senzo. This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50122C00041. About Senzo: Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products. Senzo was founded with the vision of utilizing novel technologies focussed on enhanced sensitivity, to create mobile, point-of-care, self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare professionals and patients need it most. Senzo is creating game-changing products to bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms. With insights generated at the point of care, patients can make better decisions faster, and healthcare professionals can identify life-threatening diseases at an earlier stage, improving treatment outcomes and saving lives. www.senzo.com. Contact Information: Alex Mohacs Sales & Marketing alex@senzo.com Press Release Service by Newswire.com Original Source: Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test The post Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test first appeared on Enrose Magazine. Continue Reading
Health News Candice Swanepoel’s 10-Minute Guide to “Fake Natural” Makeup and Faux Freckles | Beauty Secrets admin, October 27, 2022 Victoria’s Secret model Candice Swanepoel reveals how to do sunkissed skin, faux freckles, and the perfect lip tint on camera. Shop this beauty routine: Heritage Store Rosewater & Glycerin Spray: Dermacolor Concealer: Stila Convertible Color Blush: MAC Haute & Naughty Lash Mascara: Palmer’s Cocoa Butter Formula with Vitamin E Swivel Stick: NARS Velvet Matte Lip […] Continue Reading
Health News Jaime Carragher goes to Liverpool’s media day | CBS Sports Golazo admin, October 27, 2022 Stream every UEFA Champions League match live on Paramount+: Liverpool legend, Jaime Carragher, goes to their media day Continue Reading